A1 Refereed original research article in a scientific journal
Post-COVID-19 condition in prospective inpatient and outpatient cohorts
Authors: Hurme, Antti; Viinanen, Arja; Teräsjärvi, Johanna; Jalkanen, Pinja; Feuth, Thijs; Löyttyniemi, Eliisa; Vuorinen, Tytti; Kantele, Anu; Oksi, Jarmo; He, Qiushui; Julkunen, Ilkka
Publisher: Springer Science and Business Media LLC
Publishing place: BERLIN
Publication year: 2025
Journal: Scientific Reports
Journal name in source: Scientific Reports
Journal acronym: SCI REP-UK
Article number: 6925
Volume: 15
Issue: 1
Number of pages: 12
ISSN: 2045-2322
eISSN: 2045-2322
DOI: https://doi.org/10.1038/s41598-025-90819-1
Web address : https://doi.org/10.1038/s41598-025-90819-1
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/491269691
Viral persistence, immune dysregulation, hypocortisolism, and pulmonary tissue damage from acute infection are proposed as pathogenic mechanisms underlying post-COVID-19 condition (PCC). In this prospective observational study, we followed 62 COVID-19 inpatients and 53 COVID-19 outpatients for 24 months after the infection. During this period, we assessed prolonged symptoms, lung function, and a set of immunological markers and a proportion of the patient group was assessed with computed tomography three months post-infection. The prevalence of PCC, as assessed by four medical specialists, decreased from 51% at three months to 18% at 24 months. Risk factors included the severity of the acute infection and comorbidities of obstructive sleep apnea or obesity. Patients with PCC had higher serum levels of anti-SARS-CoV-2 S1 and N protein antibodies. In the whole group, spirometry results, orthostatic hypotension, or levels of soluble suppression of tumorigenicity 2, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), or cortisol had no association with PCC. However, using symptom clusters, patients with cognitive problems had lower cortisol levels, while patients with ongoing respiratory or myalgic symptoms had higher levels of IL-6 and hs-CRP. However, more extensive studies with clustering are needed to validate these results.
Downloadable publication This is an electronic reprint of the original article. |  |
Funding information in the publication:
This study was funded by the Academy of Finland (Grant Number 337530), Jane and Aatos Erkko Foundation (Grant Numbers 3067-84b53 and 5360-cc2fc), Wellbeing Services County of Lapland, the Sigrid Jusélius Foundation (Grant Number 240045) and Tampere Tuberculosis Foundation (Grant Number 26006205).
